Arphra
live
S&P 5000.31
NASDAQ0.00
DOW49,602.49
VIX18.06
US10Y4.47
EUR/USD1.1530
GOLD4,349.3
WTI91.36
BTC63,064.99
S&P 5000.31
NASDAQ0.00
DOW49,602.49
VIX18.06
US10Y4.47
EUR/USD1.1530
GOLD4,349.3
WTI91.36
BTC63,064.99

LAURUSLABS.BO

Laurus Labs Limited
HealthcareDrug Manufacturers - Specialty & GenericININRPeers →Country macro →
$1,447.00
Jun 05, 2026
AI Brief
Market cap
$781.07B
52w range
P / E
EPS · FY 2026
$16.45
Volume
Revenue · FY 2026
$68.13B

Explain this page

Arphra AI
Business description
· company · SEC profile

Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Founded
IPO
Dec 19, 2016
Employees
6,007
HQ
Hyderabad
CEO
Satyanarayana Chava
CFO
Exchange
BSE
Fiscal year
Identifiers
· company_identifiers
CIK
CUSIP
ISININE947Q01028
FIGILAURUSLABS IB
LEI